Hyperfine rises as portable MRI contrast study begins

Hyperfine

15/01/2026 13:41

** Shares of medical device maker Hyperfine HYPR.O rise 3.2% to $1.28 premarket

** Co says it enrolled first patient in U.S. study testing contrast agents with its portable MRI system called Swoop

** Study aims to see if gadolinium-based agents improve brain scans for conditions like tumors and inflammation, per co

** About 70 patients to participate; results expected to support FDA submission for expanded use by end-2026 - HYPR

** Contrast agents help doctors detect brain lesions and blood-brain barrier issues

** Contrast agents are substances used in MRI scans to make certain tissues or abnormalities, like tumors or inflammation, more visible to doctors

** As of last close, stock up ~11% over the past year

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))